Tylenol's crisis manager Lawrence Foster dies at 88

Share this article:

The man behind Johnson & Johnson's legend-making response to the 1982 Tylenol poisoning scare has died. The New York Times reports that Lawrence Foster, a former journalist and head of J&J's PR department, died at the age of 88. Foster had cancer and heart failure.

Under Foster's direction, the company halted all Tylenol advertising and pulled more than 30 million bottles off the shelves. Seven died after consuming capsules that had been tampered with after production and cyanide was added to capsules already on store shelves. According to a University of Florida project about the crisis, Tylenol's hold on the market fell from 37% to 7%.

Foster advised Johnson & Johnson's then-chair James Burke to be the face of the reputation campaign that is now a touchstone of crisis management and led to the brand rising to a 30% market share after the product returned to stores. Foster's strategy was to provide a human element and ownership of the crisis, without polish. Then-chair of McNeil, David Collins, tells the Times Foster's direction was “tell them what we know, and we're not going to tell them what we don't know. We'll tell them we don't know, and we'll get back to them when we do know.”

The company's multi-prong strategy for regaining consumer confidence included tamper-resistant packaging (and replacing capsules with caplets), consumer discounts, and sending sales reps into the field to talk to doctors about the product's integrity.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.